Authors
Latest:
Ten integrated imperatives for pharma commercial transformationThe pharma industry needs to go farther in adapting to new marketplace realities
Latest:
Adopting the TAPA cargo security standards in the pharmaceutical industrySecuring your supply chain
Latest:
Economic Considerations For REMSDrug sponsors have options in both how the new FDA risk programs are structured and how to execute them
Latest:
Improving health outcomes through customized adherence messagesOptimized multichannel communications will prevent illness and save lives
Latest:
Is There Life After the Lab?Today’s uncertain work environment obliges you to manage your career and financial status to keep your options open
Latest:
Future look: The Impact of Biosimilars on OncologyMarketing strategies will adjust with the advent of biosimilars
Latest:
Forecasting Returns When Patents ExpireOverestimating product reserves as loss of exclusivity (LoE) approaches can be a $75-million mistake
Latest:
CAR-T Therapies: Three Supply Chain ConsiderationsAs more of these novel—and costly—cell therapies gain approval, revamped strategies around scaling, coordination and workflow are critical to their launch
Latest:
HPCLC Spring Meeting recapLogistics managers in life sciences and personal care focus on transportation capacity
Latest:
Lessons learned on bona fide service fees and fair market value-is there a 'right answer'?Recent regulatory actions and court cases highlight the importance of due diligence in reporting the value of service fees when federal reimbursements are concerned. The financial consequences can be substantial
Latest:
True Software-as-a-Service (SaaS) Transforms Sales Automation Systems to Make Upgrades PainlessMulti-tenant sales-force automation (SFA) systems are coping with an increasingly complex regulatory environment
Latest:
In an EHR era, adverse event reporting takes on a new lookAs the number of adverse events (AEs) grows year by year, regulators and industry managers are looking at automated systems to handle the burden
Latest:
Cancer care in the US -- looking back, looking forwardBegin thinking of your business as a 'disease' company vs. a 'drug' company
Latest:
Supporting pharma’s shift in focus from patient 'outputs’ to ‘outcomes’The rise of the patient voice and increased acceptance of remote engagement are sparking a culture change across the supply chain
Latest:
The dynamic evolution of multi-sponsor REMSRisk Evaluation & Mitigation Strategy (REMS) programs are evolving, with new complexities for compliance managers
Latest:
The stakes are high in the debate over follow-on biologicsCould proposed legislation undercut the promise of targeted therapies?
Latest:
Biosimilars: It's a matter of timeFor global markets, there is a need to balance the imperative to get to market quickly against the evolving regulatory landscape
Latest:
Strategies for effective patient services programsAddressing continued hurdles in patient adherence
Latest:
The power of visualization in patient educationVisual aids, diminished for a time as a marketing and educational tool because of industry restrictions, are making a comeback
Latest:
Artificial Intelligence: Beyond the glamorIt takes gritty work to make an AI application succeed—but it can be worth the effort
Latest:
Coverage -- Access: Pharma Must Play Activist Role in Health Reform EffortsPrivate and public sectors can collaborate to achieve meaningful reform
Latest:
Biopharma Sales and Marketing Process Changes Are Failing to Keep up With Industry EvolutionBetter internal collaboration within companies is critical to improving the vital physician-rep relationship
Latest:
Rare disease patient supportRare diseases are hard to treat; supporting the patient can be even more challenging
Latest:
Extend Sampling Programs With Telemarketing and Direct MailA biopharma marketer uses direct mail and a call center to access hard-to-reach physicians
Latest:
Biopharma cold-chain market forecastMore biologic-based therapies translates into more cold chain activity. As yet, new cellular and genetic therapies are a minute part of the overall market.
Latest:
A case study in differing approaches to reimbursement approval in Europe and the USLooking at 'cost' and 'value' under different evaluation processes
